Cyred EQ® is an AB-rated generic oral contraceptive.
Apri®, Cyred®, Emoquette®, Enskyce™, Isibloom™, and Reclipsen™
The Product Information Sheet features a summary of all relevant product information including Cyred EQ® (desogestrel and ethinyl estradiol tablets, USP) 0.15 mg/0.03 mg product details, product description, NDC number, and product features.Download Now
Breakthrough bleeding and spotting are sometimes encountered in patients on oral contraceptives, especially during the first three months of use. Nonhormonal causes should be considered and adequate diagnostic measures taken to rule out malignancy or pregnancy in the event of breakthrough bleeding. Some women may encounter post-pill amenorrhea or oligomenorrhea, especially when such a condition was pre-existent.
Ectopic as well as intrauterine pregnancy may occur in contraceptive failures.
Common side effects of oral contraceptives include irregular vaginal bleeding or spotting, change in vision or difficulty wearing contact lenses, fluid retention, darkening of the skin, nausea and vomiting, change in appetite, headache, nervousness, depression, dizziness, loss of scalp hair, rash, vaginal infections, and allergic reactions.
The use of oral contraceptives is associated with increased risks of several serious conditions including myocardial infarction, thromboembolism, stroke, hepatic neoplasia, and gallbladder disease, although the risk of serious morbidity or mortality is very small in healthy women without underlying risk factors.View Full Prescribing Information, Including Boxed Warning
Package Size: A Carton Containing 3 Pouches
|ANDA||1-800-331-2632 (Ext. 74591)||andanet.com||50102025423|
|Morris & Dickson||1-888-376-7409||morrisdickson.com||392514|
|R & S Northeast||1-800-262-7770||rsnortheast.com||025423|